The undifferentiated pleomorphic sarcoma market was valued at USD 240.36 Million in 2025 and is expected to grow at a CAGR of 5.10%, reaching USD 395.27 Million by 2035. Growth is driven by increasing awareness of rare cancers and ongoing development of therapeutic interventions.
Base Year
Historical Period
Forecast Period
The rising incidence of undifferentiated pleomorphic sarcoma (UPS) is fueling the need for advanced therapies, thereby, boosting market growth.
Immunotherapies like immune checkpoint inhibitors are broadening treatment alternatives for the condition, emphasizing immune mechanisms that enable the better identify and fight cancer effectively.
The United States is leading the market share with its well-developed healthcare system and considerable research funding.
Compound Annual Growth Rate
5.1%
Value in USD Million
2026-2035
*this image is indicative*
Undifferentiated pleomorphic sarcoma (UPS) is a high-grade and rare soft-tissue sarcoma. The market is witnessing growth with rising awareness for personalized medicine, and the application of immunotherapies. Regulatory approvals and funding for early diagnosis further contribute to market growth, thus, facilitating innovation in oncology care to address the complex needs of undifferentiated pleomorphic sarcoma patients.
Rising Prevalence of Undifferentiated Pleomorphic Sarcoma Drives Market Growth
The increasing incidence of undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma (MFH) is a primary factor propelling the market growth. According to the American Cancer Society, around 13,590 new cases of soft-tissue sarcoma were expected to be diagnosed in the United States in 2024, leading to approximately 5,200 deaths. The increasing awareness around the disease is creating demand for novel treatment options, thereby enhancing market growth.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on the Treatment Type Set to Witness Substantial Growth
Based on treatment type, the market is segmented into radiation therapy (external beam radiation, intraoperative radiation therapy, and others), chemotherapy, targeted drug therapy, and immunotherapy. Among these, immunotherapy is expected to dominate the market, driven by the adoption of immune checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo). These drugs function by inhibiting the PD-1 pathway, which cancer cells frequently exploit to avoid detection by the immune system. The growing advancements in molecular biology and the increasing demand for personalized medicine are anticipated to bolster market growth during the forecast period.
Based on region, the market report offers insights into the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to the presence of key pharmaceutical companies and significant healthcare spending. Strong research initiatives and governmental support for cancer research are contributing to the growth of the local market.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG is a leading pharmaceutical company, headquartered in Germany. The company develops numerous drugs, including Vitrakvi (larotrectinib). It is a TRK inhibitor for treating tumors including undifferentiated pleomorphic sarcoma with NTRK gene fusions.
Nanobiotix S.A. is a biotechnology company that develops nanomedicines for cancer treatment. The company was established in 2003 and headquartered in France. Their leading product NBTXR3, is a radio enhancer designed to improve the efficacy of radiotherapy. NBTXR3 has shown promise in treating soft tissue sarcomas, including UPS, by enhancing the tumor-killing effects of radiation therapy.
The company was founded in 1849. They have developed Sutent (sunitinib), a multi-kinase inhibitor used to treat various cancers, including certain soft tissue sarcomas.
Novartis AG is a global pharmaceutical company based in Basel, Switzerland. The focus of this company has been on Tafinlar (dabrafenib) and Mekinist (trametinib), which target specific mutations in cancers. These drugs are primarily used for melanoma but have been investigated for other cancers including solid tumors with similar mutations.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Epizyme, Inc., Gradalis, Inc., Advenchen Laboratories LLC, Philogen S.p.A, Chugai Pharmaceutical Co., Ltd., CytRx Corp., GlaxoSmithKline Plc., Agilent Technologies, Taiho Pharmaceutical Co., Ltd, KaryoPharm Therapeutics Inc., and Lytix Biopharma AS.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share